All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)” (NCT 04625647)
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (L
Study # NCT05702034 Date Opened: 02/15/2023 Closing Date: 12/09/2026 Principal Investigator: Jennifer Berkeley, MD, PhD Sponsor: Janssen Research & Development
A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain (RESET)
Study # NCT04246281 Date Opened: 06/17/2020 Closing Date: 03/31/2026 Sponsor: SPR Therapeutics
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy (STARSTIM)
Study # NCT04770337 Date Opened: 10/25/2021 Closing Date: 12/31/2024 Sponsor: Neuroelectrics Corporation
Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Study # NCT04957719 Date Opened: 08/14/2021 Closing Date: 08/31/2025 Sponsor: Idorsia Pharmaceuticals Ltd.
ThromboelAstogRaphy Guided Approach to Reduce Recurrent Events in ACS Patients Undergoing Catheter Based Intervention (TARGET-ACS)
Study # TARGET-ACS
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Study # FcGammaRIIa
A Single-Dose, Open-Label, Randomized, Multi-Center, 2-Treatment Crossover Study To Compare The Pharmacodynamics, Pharmacokinetics, Safety, And Tolerability Of Acetylsalicylic Acid Powder For Oral Inhalation With Non-Enteric-Coated Chewable Aspirin In Adu
Study # NCT05625347
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore Racial Minority Communities (M-BRACE Trial)
Study # M-BRACE Trial
A Study of the ReCor Medical Paradise System in Clinical Hypertension
Study # NCT02649426
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy parallel-group, 2-arm, Phase 3 study to compare the efficacy of the oral FXIa inhibitor asundexian with apixaban for the prevention of stroke or systemic em
Study # SCFTR-02
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Study # VICTORION-2 PREVENT
A Phase 2 Open-label Study Evaluating the Efficacy and Safety of luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum resistant epithelial ovarian cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate
Study # GOG 3086 / STRO-002-GM3 Date Opened: 09/21/2023 (Pharma) Principal Investigator: Pallavi Kumar, M.D.
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cel
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
